<DOC>
	<DOCNO>NCT02680574</DOCNO>
	<brief_summary>A multicenter , randomize , open-label , active-controlled Phase 3 study maintenance treatment anemia subject NDD-CKD</brief_summary>
	<brief_title>Efficacy Safety Study Evaluate Vadadustat Maintenance Treatment Anemia Subjects With Non-dialysis-dependent Chronic Kidney Disease ( NDD-CKD )</brief_title>
	<detailed_description>This multicenter , randomize , open-label , active-controlled Phase 3 study efficacy safety vadadustat versus darbepoetin alfa maintenance treatment anemia subject NDD-CKD</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>≥18 year age Diagnosis CKD eGFR ≤60 mL/min/1.73 m^2 Screening expect start dialysis within 6 month Screening Currently maintain ESA therapy , last dose receive within 8 week prior Screening Mean Screening HGB 8.0 11.0 g/dL ( inclusive ) US 9.0 12.0 g/dL ( inclusive ) outside US Uncontrolled hypertension Severe heart failure Screening ( New York Heart Association Class IV ) Acute coronary syndrome ( hospitalization unstable angina myocardial infarction ) , urgent coronary revascularization , hospitalization CHF , stroke within 12 week prior Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>vadadustat</keyword>
	<keyword>AKB-6548</keyword>
	<keyword>Chronic kidney disease</keyword>
	<keyword>anemia</keyword>
	<keyword>CKD</keyword>
	<keyword>chronic renal insufficiency</keyword>
	<keyword>renal impairment</keyword>
	<keyword>erythropoietin</keyword>
	<keyword>kidney</keyword>
	<keyword>renal</keyword>
	<keyword>oral anemia treatment</keyword>
	<keyword>hemoglobin</keyword>
	<keyword>hypoxia-inducible factor</keyword>
	<keyword>HIF</keyword>
	<keyword>hypoxia-inducible factor prolyl-hydroxylase inhibitor</keyword>
	<keyword>HIF-PHI</keyword>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
	<keyword>Phase 3</keyword>
	<keyword>cardiovascular</keyword>
	<keyword>NDD-CKD</keyword>
</DOC>